SAN DIEGO--(BUSINESS WIRE)--PURE Bioscience (NASDAQ: PURE) today announced that based on encouraging preclinical data it has granted two product-specific licenses to pharmaceutical development partner FTA Bioscience for development of a silver dihydrogen citrate (SDC)-based treatment for tinea unguium, also referred to as onychomycosis (nail fungus), as well as for tinea pedis (athlete’s foot).
